Literature DB >> 27708928

Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers.

Ediz Dalkılıç1, Mustafa Ferhat Öksüz1, Ayşe Nur Tufan1, Aysun Özbek1, Ali Nizamoğlu1, Mürside Esra Dolarslan1, Belkıs Nihan Coşkun1, Yavuz Pehlivan1.   

Abstract

OBJECTIVE: Rheumatoid factor (RF) positivity that may occur in a number of patients with hepatitis B (HBV) infection poses challenges in terms of differential diagnosis with rheumatoid arthritis (RA). On the other hand, antibodies to cyclic citrullinated peptide (anti-CCP) may prove to be an important marker for differential diagnosis of the two conditions. This study aimed to assess anti-CCP and RF positivity among patients with hepatitis B and rheumatoid arthritis.
MATERIAL AND METHODS: Anti-CCP and RF seropositivity was assessed in 61 patients with HBV infection (32 patients with chronic hepatitis, 29 patients with inactive HBV carrier status) and 40 patients with RA as the control group.
RESULTS: RF positivity was found in 18.7% and 34.4% of the patients with chronic hepatitis B and inactive HBV carrier status, respectively. On the other hand, only one patient with chronic HBV had low positive anti-CCP. RF was positive in 24 (60%) and anti-CCP was positive in 26 (65%) patients among the 40 patients with RA.
CONCLUSION: Anti-CCP may be helpful in the differential diagnosis between RA and chronic HBV infection or inactive HBV carrier status.

Entities:  

Keywords:  Hepatitis B; anti-cyclic citrullinated peptide; rheumatoid arthritis; rheumatoid factor

Year:  2015        PMID: 27708928      PMCID: PMC5047264          DOI: 10.5152/eurjrheum.2015.0101

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  20 in total

Review 1.  Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link.

Authors:  A Csepregi; E Nemesanszky; B Rojkovich; G Poor
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

2.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

3.  An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers.

Authors:  K Watanabe; Y Ohkubo; Y Funahashi; T Nishimaki; T Moritoh; R Kasukawa; S Kaise; T Tomita; A Matsukawa
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

4.  Expression and clinical significance of antinuclear antibody in hepatitis C virus infection.

Authors:  Y C Peng; S C Hsieh; D Y Yang; C F Tung; W H Hu; W N Huang; G H Chen
Journal:  J Clin Gastroenterol       Date:  2001 Nov-Dec       Impact factor: 3.062

5.  Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia.

Authors:  Feng-Cheng Liu; You-Chen Chao; Tsung-Yun Hou; Hsiang-Cheng Chen; Rong-Yaun Shyu; Tsai-Yuan Hsieh; Chen-Hung Chen; Deh-Ming Chang; Jenn-Haung Lai
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

6.  Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.

Authors:  Mark H Wener; Kathleen Hutchinson; Chihiro Morishima; David R Gretch
Journal:  Arthritis Rheum       Date:  2004-07

7.  Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.

Authors:  Mi-Kyoung Lim; Dong-Hyuk Sheen; Yun Jung Lee; You Ri Mun; Mira Park; Seung-Cheol Shim
Journal:  J Rheumatol       Date:  2009-03-13       Impact factor: 4.666

8.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.

Authors:  Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans
Journal:  Arthritis Rheum       Date:  2004-02

9.  Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

Authors:  D M Lee; P H Schur
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

10.  The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Authors:  E Orge; A Cefle; Ayten Yazici; N Gürel-Polat; S Hulagu
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

View more
  1 in total

1.  Prevalence and relevant factors of positive RF in brucellosis patients with arthralgia.

Authors:  Siwen Zhang; Jing Hu; Shuqi An; Mujinyan Li; Fande Li; Peng Zhang; Xiangyi Zhang; Huixin Yang; Taijun Wang; Jingjing Luo; Fangfang Hu; Jiashuo Liu; Qing Zhen
Journal:  PLoS Negl Trop Dis       Date:  2021-09-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.